|Mr. L. Daniel Browne||Co-Founder, CEO, Pres & Director||783.49k||N/A||1962|
|Dr. Abhay Joshi||Chief Operating Officer||800.88k||N/A||1963|
|Mr. Todd Erik Zavodnick||Chief Commercial Officer and Pres of Aesthetics & Therapeutics||N/A||N/A||1972|
|Ms. Lauren P. Silvernail||CFO, Chief Bus. Officer & Sec.||651.86k||N/A||1959|
|Ms. Jeanie D. Herbert||Sr. Director of Investor Relations & Corp. Communications||N/A||N/A||N/A|
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacturing, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic indications. The company's drug candidate is DaxibotulinumtoxinA for injection (RT002), which is in phase III clinical trials to treat glabellar (frown) lines, as well as in phase II clinical trials for the treatment of cervical dystonia and plantar fasciitis. It is also developing DaxibotulinumtoxinA topical gel (RT001) that is in preclinical development. Revance Therapeutics, Inc. has a collaboration agreement with Mylan N.V. (MYL) for the development, manufacture, and commercialization of a biosimilar to BOTOX. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was founded in 1999 and is headquartered in Newark, California.
Revance Therapeutics, Inc.’s ISS Governance QualityScore as of May 1, 2018 is 8. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 8; Compensation: 9.